StocksMedium•25 September 2026•
1 min read
FDA Approves Mirum and Incyte's Atebrioz for Rare Genetic Disorder
Key Facts
1The U.S. FDA approved Atebrioz (zilurgisertib) for adult and pediatric patients with fibrodysplasia ossificans progressiva (FOP).
The U.S. FDA approved Atebrioz (zilurgisertib) for the treatment of adult and pediatric patients with fibrodysplasia ossificans progressiva (FOP). Business Wire reported that the approval provides Mirum Pharmaceuticals and Incyte with a new therapeutic path for this rare genetic condition where muscle and connective tissues are replaced by bone.
The regulatory milestone followed clinical evaluations of the drug's efficacy in managing the disorder. Regarding market performance, MIRM closed at $89.36 on September 24, 2026, while INCY closed at $124.44 on the same date after reaching a session high of $125.55.